Scarica l'app Stockscreener
99.98
0.80%
0.79
Dopo l'orario di chiusura:
99.98
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Precedente Chiudi:
$99.19
Aprire:
$100.03
Volume 24 ore:
360.75K
Relative Volume:
0.49
Capitalizzazione di mercato:
$6.43B
Reddito:
$74.06M
Utile/perdita netta:
$-114.71M
Rapporto P/E:
-55.42
EPS:
-1.8039
Flusso di cassa netto:
$-117.90M
1 W Prestazione:
+1.64%
1M Prestazione:
-0.02%
6M Prestazione:
+11.00%
1 anno Prestazione:
+118.97%
Intervallo 1D:
$97.93
$100.80
Intervallo di 1 settimana:
$97.93
$103.43
Portata 52W:
$45.28
$107.84
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Nome
Protagonist Therapeutics Inc
Settore
Industria
Telefono
(510) 474-0170
Indirizzo
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
99.98 | 6.38B | 74.06M | -114.71M | -117.90M | -1.8039 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-12 | Iniziato | Leerink Partners | Outperform |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-12-06 | Iniziato | Goldman | Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-09-24 | Iniziato | TD Cowen | Buy |
| 2024-09-09 | Iniziato | Truist | Buy |
| 2023-10-30 | Iniziato | CapitalOne | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2022-08-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Buy |
| 2021-10-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-24 | Iniziato | Northland Capital | Outperform |
| 2021-01-06 | Iniziato | JP Morgan | Overweight |
| 2020-12-16 | Iniziato | Piper Sandler | Overweight |
| 2020-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Iniziato | Jefferies | Buy |
| 2020-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-05-09 | Aggiornamento | Stifel | Hold → Buy |
| 2018-12-06 | Iniziato | Nomura | Buy |
| 2018-01-29 | Iniziato | Stifel | Buy |
| 2017-07-21 | Iniziato | BTIG Research | Buy |
Mostra tutto
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Discipline and Rules-Based Execution in PTGX Response - Stock Traders Daily
Protagonist Therapeutics (NASDAQ:PTGX) Upgraded to "Strong-Buy" at Wolfe Research - MarketBeat
PTGX News | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
Wolfe Research initiates Protagonist Therapeutics stock with outperform rating - Investing.com India
Wolfe Research initiates Protagonist Therapeutics stock with outperform rating By Investing.com - Investing.com South Africa
Eagle Health Investments LP Takes $5.01 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
PTGX Stock Price, Quote & Chart | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why - MSN
HC Wainwright Issues Positive Outlook for PTGX Earnings - MarketBeat
Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock? - MSN
A Look At Protagonist Therapeutics (PTGX) Valuation After First Quarter Earnings Swing To Profit - Sahm
Protagonist Therapeutics, Inc. $PTGX Holdings Raised by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Protagonist Therapeutics Strengthens Market Buzz On Nasdaq Composite - Kalkine Media
This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year - simplywall.st
AIHC Capital Management Ltd Buys New Shares in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Behavioral Patterns of PTGX and Institutional Flows - Stock Traders Daily
(SEC Amendment) Protagonist Therapeutics(PTGX.US) Officer Sells US$7.51 Million in Common Stock - Moomoo
Protagonist Therapeutics CEO Dinesh V. Patel sells $7.5m after option exercise By Investing.com - Investing.com Australia
Protagonist Therapeutics CEO Dinesh V. Patel sells $7.5m after option exercise - Investing.com UK
PTGX (NASDAQ: PTGX) CEO sells 75K shares under 10b5-1 trading plan - Stock Titan
J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $113 - Moomoo
Protagonist Therapeutics Insider Sold Shares Worth $7,509,000, According to a Recent SEC Filing - Moomoo
Protagonist Therapeutics(PTGX.US) Officer Sells US$7.51 Million in Common Stock - Moomoo
Protagonist Therapeutics CEO Dinesh V. Patel sells $7.5m in shares - Investing.com Nigeria
Protagonist Therapeutics CEO Dinesh V. Patel sells $7.5m in shares By Investing.com - Investing.com South Africa
Protagonist Therapeutics President, CEO Sold Shares Worth Over $7.5M - TradingView
Protagonist Therapeutics (NASDAQ: PTGX) CEO sells 75,000 shares after exercising options - Stock Titan
75,000-share sale notice filed by PTGX insider (NASDAQ: PTGX) - Stock Titan
State Street Holds 3.12M Protagonist Therapeutics Shares (PTGX) - Stock Titan
Insiders At Protagonist Therapeutics Sold US$11m In Stock, Alluding To Potential Weakness - Moomoo
Protagonist Therapeutics Insider Sold Shares Worth $5,918,880, According to a Recent SEC Filing - Moomoo
Protagonist Therapeutics(PTGX.US) Director Sells US$5.92 Million in Common Stock - Moomoo
Protagonist Therapeutics director Giraudo sells $5.9m in shares By Investing.com - Investing.com Australia
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Director Sells 36,000 Shares of Stock - MarketBeat
[Form 4] Protagonist Therapeutics, Inc Insider Trading Activity - Stock Titan
Protagonist Therapeutics director Giraudo sells $5.9m in shares - Investing.com
Protagonist Therapeutics Director Sold Shares Worth Over $5.9M - TradingView
BMO reiterates Protagonist Therapeutics stock rating on launch momentum - Investing.com India
Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):